PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients-Reference-Cited by-同舟云学术

PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients

Published:2014-01-27 Issue:1 Volume:16 Page:
ISSN:1465-542X
Container-title:Breast Cancer Research
language:en
Short-container-title:Breast Cancer Res

Author:

Beelen Karin,Opdam Mark,Severson Tesa M,Koornstra Rutger HT,Vincent Andrew D,Wesseling Jelle,Muris Jettie J,Berns Els MJJ,Vermorken Jan B,van Diest Paul J,Linn Sabine C

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/bcr3606.pdf

Reference51 articles.

1. Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Badie-Lacourtoisie S, Eymard JC, Debled M, Spaeth D, Legouffe E, Allouache D, El KC, Pujade-Lauraine E: Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol. 2012, 30: 2718-2724. 10.1200/JCO.2011.39.0708.

2. Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2011, 366: 520-529.

3. Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV, Cantley LC, Brugge JS: Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 2005, 65: 10992-11000. 10.1158/0008-5472.CAN-05-2612.

4. Parsons R, Simpson L: PTEN and cancer. Methods Mol Biol. 2003, 222: 147-166.

5. Knowlden JM, Hutcheson IR, Barrow D, Gee JM, Nicholson RI: Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology. 2005, 146: 4609-4618. 10.1210/en.2005-0247.

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel markers in breast pathology;Histopathology;2022-12-05

2. Immune Checkpoint Blockade in Hormone Receptor-Positive Breast Cancer: Resistance Mechanisms and Future Perspectives;Clinical Breast Cancer;2022-10

3. Biological effects and regulation of IGFBP5 in breast cancer;Frontiers in Endocrinology;2022-08-25

4. External Validation of Two Established Clinical Risk Scores Predicting Outcome after Local Treatment of Colorectal Liver Metastases in a Nationwide Cohort;Cancers;2022-05-10

5. PI3K/AKT/MTOR: CONTRIBUTION TO THE TUMOR PHENOTYPE SENSITIVE TO TAMOXIFEN;Russian Journal of Biotherapy;2021-04-08